Document:

Repurchase Agreement dated as of August 16, 2005 by and between Venus Beauty Supply, Inc. and Panetta Partners, Ltd.

 

 

Exhibit 10.1

 

VENUS
BEAUTY SUPPLY, INC.

REPURCHASE
AGREEMENT

This
Agreement is entered into as of August 16, 2005 by and between Venus Beauty
Supply, Inc., a Florida corporation (the “Company”), and Panetta Partners Ltd.,
a Colorado limited partnership (“Shareholder”).

RECITALS

A.     
Shareholder owns 2,000,000 shares of common stock, $.001 par value per share, of
the Company (the “Old Common Stock”) of which Shareholder owns 2,000,000 shares
as of the date hereof.

 

B.     
The Company is entering into Purchase Agreements of even date herewith pursuant
to which several investors (the “Investors”) are purchasing from the Company an
aggregate of up to 6,000,000 shares of the Company’s common stock (after giving
effect to a 35.28 stock split, the “New Common Stock”) and warrants to purchase
up to an additional 900,000 shares of New Common Stock (“Warrants”) to provide
funds for an acquisition of Fermavir Research, Inc., a Delaware corporation.

 

C.     
The Investors are willing to purchase shares of New Common Stock and Warrants
(collectively the “Securities”) and the shareholders of Fermavir are willing to
exchange shares of Fermavir for shares of New Common Stock if Shareholder
significantly reduces its proportion of ownership in the Company.

AGREEMENTS

In
consideration of the foregoing and the other provisions set forth herein, the
parties hereby agree as follows:

1.        
PURCHASE 

(a)       
Subject
to the representation and warranties of Shareholder below, the Company hereby
agrees to purchase 1,918,367.34 shares of Old Common Stock (the “Purchased
Shares”) from the Shareholder for the aggregated price of $750,000 (the
“Purchase Price”) as follows:

 

	 	
      (i)
	
      $400,000
      out of the proceeds of the sale of the Securities; and

	 	 	 
	 	
      (ii)
	
      delivery
      of a note (the “Note”) payable to the Shareholder in the form annexed
      hereto as Exhibit A in the principal amount of
$350,000.

(b)       
The
closing of the purchase shall occur simultaneously with the closing of the
purchase of New Common Stock by the Investors by the Company’s delivery of the
Purchase Price to the Shareholder.

1

 

(c)       
This
Agreement shall serve as a written instruction of the Shareholder to the Company
to record the transfer of the Purchased Shares to the Company and, at the
Company’s option, the cancellation of the Purchased Shares.

2.        
REPRESENTATIONS
OF THE SHAREHOLDER 

The
Shareholder represents and warrants to the Company as of the date of this
Agreement and as of the date of the Closing as follows:

(a)       
Ownership
of Stock. Shareholder
is the lawful owner of the Purchased Shares free and clear of all preemptive or
similar rights, liens, encumbrances, restrictions and claims of every kind.
Shareholder has full legal right, power and authority to enter into this
Agreement and to sell, assign, transfer and convey the Purchased Shares so owned
by such Shareholder pursuant to this Agreement and the delivery to the Company
of the Purchased Shares by such Shareholder pursuant to the provisions of this
Agree-ment will transfer to Purchaser valid title thereto, free and clear of all
liens, encumbrances, restrictions and claims of every kind. 

(b)       
Authority
to Execute and Perform Agreement; No Breach.
Shareholder has the full legal right and power and all authority and approval
required to enter into, execute and deliver this Agreement, and to sell, assign,
transfer and convey the Purchased Shares and to perform fully its obligations
hereunder. This Agreement has been duly executed and delivered by such
Shareholder and, assuming due execution and delivery by, and enforceability
against, the Company, constitutes the valid and binding obligation of
Shareholder enforceable in accordance with its terms, subject to the
qualifications that enforcement of the rights and remedies created hereby is
subject to (i) bankruptcy, insolvency, reorganization, moratorium and other laws
of general application affecting the rights and remedies of creditors, and (ii)
general principles of equity (regardless of whether such enforcement is
considered in a proceeding in equity or at law). No approval or consent of, or
filing with, any governmental or regulatory body, and no approval or consent of,
or filing with, any other person is required to be obtained by Shareholder or in
connection with the execution and delivery by Shareholder of this Agreement and
consummation and performance by them of the transactions contemplated hereby.
The execution, delivery and performance of this Agreement by Shareholder and the
consummation of the transactions contemplated hereby in accordance with the
terms and conditions hereof by Shareholder will not:

	 	
      (i)
	
      knowingly
      violate, conflict with or result in the breach of any of the material
      terms of, or constitute (or with notice or lapse of time or both would
      constitute) a material default under, any contract, lease, agreement or
      other instrument or obligation to which Shareholder is a party or by or to
      which any of the properties and assets of Shareholder may be bound or
      subject;

	 	
      (ii)
	
      violate
      any order, judgment, injunction, award or decree of any court, arbitrator,
      governmental or regulatory body, by which either Shareholder or the
      securities, assets, properties or business of Shareholder is bound; or
      

 

2

 

	 	
      (iii)
	
      knowingly
      violate any statute, law or regulation.

(c)       
Restrictive
Agreements.
Shareholder
is not subject to, or a party to, mortgage, lien, lease, license, permit,
agreement, contract, instrument, law, rule, ordinance, regulation, order,
judgment or decree, or any other restriction of any kind or character, which
would prevent consummation of the transactions contemplated by this Agreement,
compliance by Shareholder with the terms, conditions and provisions of which
would restrict the ability of the Company to acquire any property or conduct its
business as conducted or proposed to be conducted.

(d)       
Broker’s
or Finder’s Fees.
No agent, broker, person or firm acting on behalf of the Shareholders is, or
will be, entitled to any commission or broker’s or finder’s fees from any of the
parties hereto, or from any person controlling, controlled by or under common
control with any of the parties hereto, in connection with any of the
transactions contemplated by this Agreement.

3.        
COUNTERPARTS

This
Agreement may be executed in any number of counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same
instrument.

4.        
AMENDMENT

This
Agreement shall not be subject to modification or amendment in any respect,
except by an instrument in writing signed by Shareholder and on behalf of the
Company and approved by its Board of Directors.

5.        
GOVERNING LAW

This
Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of New York, without regard to principles of conflict
of laws.

6.        
ARBITRATION

Any
controversies or claims arising out of or relating to this Agreement shall be
fully and finally settled by arbitration in accordance with the Commercial
Arbitration Rules of the American Arbitration Association (the “AAA Rules”),
conducted by one arbitrator either mutually agreed upon by the parties or chosen
in accordance with the AAA Rules, except that the parties thereto shall have any
right to discovery as would be permitted by the Federal Rules of Civil Procedure
for a period of 90 days following the commencement of such arbitration, and the
arbitrator thereof shall resolve any dispute which arises in connection with
such discovery. Arbitration proceedings shall be conducted in New York, New
York.

7.        
NOTICES

All
notices, demands or other communications desired or required to be given by any
party to any other party hereto shall be in writing and shall be deemed
effectively given upon (a)

 

3

 

personal
delivery to the party to be notified, (b) upon confirmation of receipt of
telecopy or other electronic facsimile transmission, (c) one business day after
deposit with a reputable overnight courier, prepaid for priority overnight
delivery and addressed as set forth in (d), or (d) five days after deposit with
the United States Post Office, postage prepaid, and addressed as follows: (i) if
to Shareholder, to 1275 First Avenue, Suite 296, New York, NY 10021, at the
address and facsimile number of the Company’s then current executive offices;
(ii) if to the Company, at the address and facsimile number of the Company’s
then current executive offices; or (iii) to such other addresses and to the
attention of such other individuals as any party shall have designated to the
other parties by notice given in the foregoing manner.

8.        
SEVERABILITY

If one or
more provisions of this Agreement are held to be unenforceable under applicable
law, such provisions shall be excluded from this Agreement and the balance of
this Agreement shall be interpreted as if such provisions were so excluded and
shall be enforceable in accordance with its terms.

9.        
ENTIRE AGREEMENT

This
Agreement constitutes the full and entire understanding and agreement of the
parties with respect to the subject matter hereof and supersedes all prior
agreements with respect to the subject matter hereof.

[SIGNATURE
PAGE FOLLOWS]

 

4

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day
and year first above written.

 

	 	 	 
	 	VENUS BEAUTY SUPPLY,
    INC.
	 
 	 
 	 
 
		By:  	/s/
      Sarah Boothe
	 	
      

    
	 	Sarah Boothe,
President

 

	 	 	 
	 	PANETTA PARTNERS
  LTD.
	 
 	 
 	 
 
		By:  	/s/
      Gabriele M. Cerrone
	 	
      

    
	 	
      Gabriele
      M. Cerrone, Managing Partner

 

5

 

EXHIBIT
A

 

NOTE

 

 

6Consulting Agreement dated as of August 16, 2005 by and between Gabriele M. Cerrone and Venus Beauty Supply, Inc.

 

 

Exhibit 10.2

 

 

CONSULTING
AGREEMENT

This Agreement is made and entered into as of
the 16th day of August, 2005 by and between Gabriele M. Cerrone
(“Consultant”) and Venus Beauty Supply, Inc,. a Florida corporation, (the
“Company”).

WHEREAS,
the Consultant has assisted the Company in the acquisition of Fermavir Research,
Inc., its recapitalization and initial financing, and advised Fermavir’s
management in strategic planning and the development of strategic relationships;
and 

WHEREAS,
the Company’s management and Board of Directors wishes to assure that the
Company will continue to have the services of the Consultant available to
it.

WHEREAS,
the Company desires to engage Consultant to provide certain consulting services,
and Consultant is willing to be engaged by the Company to provide such services,
on the terms and conditions set forth below;

NOW,
THEREFORE, in consideration of the mutual covenants and agreements contained
herein, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:

1.        
Purpose: The
Company hereby engages Consultant for the term specified in Paragraph 2 hereof
to render consulting advice to the Company relating to business development,
corporate finance and capital markets matters upon the terms and conditions set
forth herein.

2.        
Effective
Date and Term: 

2.1       
Effective
Date. This
Agreement shall become effective on the earlier of the Company’s receipt of at
least $750,000 of financing after September 1, 2005 or November 15, 2005 (the
“Effective Date”).

 

2.2       
Term. Unless
earlier terminated pursuant to Section 10 hereof, the term of this Agreement
shall commence on the Effective Date and shall continue from the Effective Date
to the third anniversary thereof (the “Initial Term”). This Agreement shall
thereafter be automatically renewed for successive one year periods (each a
“Renewal Term”) unless either party shall notify the other in writing of its
intention not to renew this Agreement (a “Non-renewal Notice”), which notice
shall be given at least 90 days prior to the end of the then current term (the
“Expiration Date”). The period from the Commencement Date to the Expiration
Date, including the Renewal Term, if any, is referred to herein as the
“Term.”

 

3.        
Duties
of Consultant: During
the term of this Agreement, the Consultant shall devote such portion of his
business time and attention to affairs of the Company reasonably necessary to
provide the Company with such regular and customary business development,
strategic planning, capital markets and corporate finance consulting advice as
is reasonably requested by the Company’s management and Board of Directors,
provided that Consultant shall

 

1

 

not be
required to undertake duties not reasonably within the scope of this Agreement,
nor shall Consultant be required to provide any of the services set forth in
Section 3.2 hereof. So long as the Consultant serves as a member of the
Company’s Board of Directors, Consultant shall serve as Chairman of the
Board.

 

3.1.
Permissible
Services. The
Consultant’s services will include advising the Company’s Board of Directors and
senior management on the following matters:

	 	
      (i)
	
      in-licensing
      and out-licensing technologies and
compounds;

	 	
      (ii)
	
      capitalization
      and corporate organization of the Company;

	 	
      (iii)
	
      structure
      and pricing of offerings of the Company’s securities in public and private
      transactions;

	 	
      (iv)
	
      alternative
      uses of corporate assets;

	 	
      (v)
	
      structure
      and use of debt;

	 	
      (vi)
	
      application
      and maintenance of listing of the Company’s stock in securities exchanges
      and other appropriate markets; 

	 	
      (vii)
	
      strategic
      planning

	 	
      (viii)
	
      management
      recruitment and compensation; and

	 	
      (ix)
	
      presentations
      to institutional and professional individual investors in the U.S. and
      Europe.

3.2       
Prohibited
Services. The
services to be rendered by the Consultant to the Company shall not (unless the
Consultant is appropriately licensed, registered or there is an exemption
available from such licensing or registration) include, directly or indirectly:
any activities which require the Consultant to register as a broker-dealer under
the Securities Exchange Act of 1934.

4.        
Compensation: In
consideration for the services rendered by Consultant to the Company pursuant to
this Agreement, the Company agrees to pay Consultant the annual sum of $198,000
at the rate of $16,500 per month commencing on the Effective Date (“Base
Compensation”). The Consultant’s Base Compensation may be increased, but not
decreased by the Compensation Committee of the Company’s Board of Directors (or
similar committee serving that function, the “Committee”). Once increased, such
increased amount shall constitute the Consultant’s Base Compensation and shall
not be decreased. In addition, Consultant shall be granted periodically options
under the Company’s various equity incentive plans commensurate with and having
the same term and conditions as those granted to the Company’s senior executive
officers. The Company will include the shares of equity securities of the
Company which may be issued upon the exercise of the options in any registration
statement under the Securities Act of 1933 which includes securities issuable to
any other executive officer of the Company. The Consultant shall be eligible to
earn a cash bonus of up to 15% of Base Compensation for each calendar year of
the Term (or portion thereof) based on meeting performance objectives and bonus
criteria to be mutually identified by Consultant and the Company’s Board of
Directors. 

2

 

5.        
Expenses
and Services: 

5.1       
Consultant
is authorized to incur reasonable expenses in carrying out his duties and
responsibilities under this Agreement, including, without limitation, expenses
for research services, travel, cellular telephone (including access charges and
business calls), and business entertainment. Additionally, Consultant shall,
after having obtaining the approval of the Company’s Chief Financial Officer,
which shall not be unreasonably withheld, be authorized to incur reasonable
expenses for the attendance of conferences in fields relating to therapeutic
technologies, technology of interest to the Company, finance of biotechnology
ventures, and similar items related to Consultant’s duties and responsibilities
as Consultant deems necessary. Company will reimburse Consultant for all such
expenses upon presentation by Consultant of appropriately itemized accounts of
such expenditures or the Company will pay such expenses directly.

 

5.2      
During
the Term, Consultant shall be provided with office facilities and access to
Company information and financial records and an experienced administrative
assistant (which may be shared with no more than one senior executive officer)
as is deemed appropriate by the Consultant and approved by the Company’s Chief
Financial Officer and in the absence of a CFO, the Company’s CEO. Such services
and facilities will not be diminished without the Consultant’s prior
consent.

6.        
Liability
of Consultant: The
Company acknowledges that all opinions and advice (written or oral) given by
Consultant to the Company in connection with Consultant’s engagement are
intended solely for the benefit and use of the Company in considering the
transaction to which they relate, and the Company agrees that no person or
entity other than the Company shall be entitled to make use of or rely upon the
advice of Consultant to be given hereunder, and no such opinion or advice shall
be used for any other purpose or reproduced, disseminated, quoted or referred to
at any time, in any manner or for any purpose, nor may the Company make any
public references to Consultant, or use Consultant’s name in any annual reports
or any other reports or releases of the Company without Consultant’s prior
written consent. Consultant’s maximum liability shall not exceed the cash
compensation received from the Company.

7.        
Consultant’s
Services to Others: The
Company acknowledges that Consultant and its affiliates are in the business of
investing in and providing financial and strategic consulting services to
others. Nothing herein contained shall be construed to limit or restrict
Consultant in conducting such business with respect to others, or in rendering
such advice to others.

8.        
Company
Information:

a.       
The
Company recognizes and confirms that, in advising the Company and in fulfilling
it engagement hereunder, Consultant will use and rely on data, material and
other information furnished to Consultant by the Company. The Company
acknowledges and agrees that in performing its services under this engagement,
Consultant may rely upon the data, material and other information supplied by
the Company without independently verifying the accuracy, completeness or
veracity of same. The Company agrees to notify Consultant in

 

3

 

writing
via overnight courier, facsimile or e-mail of any material event and/or change
with in twenty-four hours of its occurrence.

b.       
Consultant
recognizes and acknowledges that by reason of Consultant’s retention by and
service to the Company before, during and, if applicable, after the Term,
Consultant will have access to certain confidential and proprietary information
relating to the Company’s business, which may include, but is not limited to,
trade secrets, trade “know-how,” product development techniques and plans,
formulas, customer lists and addresses, financing services, funding programs,
cost and pricing information, marketing and sales techniques, strategy and
programs, computer programs and software and financial information relating
to the field of in which the Company is actually engaged in research,
development, collaboration or sales at the time of such disclosure (collectively
referred to as “Confidential Information”). Consultant acknowledges that such
Confidential Information is a valuable and unique asset of the Company and
Consultant covenants that it will not, unless expressly authorized in writing by
the Company, at any time during the Term use any Confidential Information or
divulge or disclose any Confidential Information to any person, firm or
corporation except in connection with the performance of Consultant’s duties for
the Company and in a manner consistent with the Company’s policies regarding
Confidential Information. Consultant also covenants that at any time after the
termination of this Agreement, directly or indirectly, it will not use any
Confidential Information or divulge or disclose any Confidential Information to
any person, firm or corporation, unless such information is in the public domain
through no fault of Consultant or except when required to do so by a court of
law, by any governmental agency having supervisory authority over the business
of the Company or by any administrative or legislative body (including a
committee thereof) with apparent jurisdiction to order Consultant to divulge,
disclose or make accessible such information. All written Confidential
Information (including, without limitation, in any computer or other electronic
format) which comes into Consultant’s possession during the Term shall remain
the property of the Company. Except as required in the performance of
Consultant’s duties for the Company, or unless expressly authorized in writing
by the Company, Consultant shall not remove any written Confidential Information
from the Company’s premises, except in connection with the performance of
Consultant’s duties for the Company and in a manner consistent with the
Company’s policies regarding Confidential Information. Upon termination of this
Agreement, the Consultant agrees to return immediately to the Company all
written Confidential Information (including, without limitation, in any computer
or other electronic format) in Consultant’s possession. .

 

9.        
Consultant
an Independent Contractor:
Consultant shall perform its services hereunder as an independent contractor and
not as an employee of the Company or an affiliate thereof. It is expressly
understood and agreed to by the parties hereto that Consultant shall have no
authority to act for, represent or bind the Company or any affiliate thereof in
any manner, except as may be agreed to expressly by the Company in writing from
time to time.

10.       Termination:

10.1     
Termination
Without Cause or for Good Reason. 

(a)       
If this
Agreement is terminated by the Company other than for Cause (as defined in
Section 10.4 hereof) as a result of Consultant’s death or Permanent

 

4

 

Disability
(as defined in Section 10.2 hereof), or if Consultant terminates his employment
for Good Reason (as defined in Section 10.1 (b) hereof) prior to the Expiration
Date, Consultant shall receive or commence receiving as soon as practicable in
accordance with the terms of this Agreement:

	 	
      (i)
	
      a
      severance payment (the “Severance Payment”), which amount shall be paid in
      a cash lump sum within ten (10) days of the date of termination, in an
      amount equal to the aggregate amount of the Consultant's Base Compensation
      for the then remaining term of this
Agreement;

	 	
      (ii)
	
      immediate
      vesting of all unvested stock options and the extension of the exercise
      period of such options to the later of the longest period permitted by the
      Company’s stock option plans or ten years following the Termination
      Date;

	 	
      (iii)
	
      payment
      in respect of compensation earned but not yet paid (the “Compensation
      Payment”) which amount shall be paid in a cash lump sum within ten (10)
      days of the date of termination; and 

(b)       
For
purposes of this Agreement, “Good Reason” shall mean any of the following
(without Consultant’s express prior written consent):

	 	
      (i)
	
      Any
      material breach by Company of any provision of this Agreement, including
      any material reduction by Company of Consultant’s duties or
      responsibilities (except in connection with the termination of
      Consultant’s employment for Cause, as a result of Permanent Disability, as
      a result of Consultant's death or by Consultant other than for Good
      Reason);

	 	
      (ii)
	
      A
      reduction by the Company in Consultant’s Base Compensation or any failure
      of the Company to reimburse Consultant for material expenses described in
      Section 5.1 or provide the services described in Section 5.2 of this
      Agreement;

	 	
      (iii)
	
      The
      failure by the Company to obtain the specific assumption of this Agreement
      by any successor or assign of Company as provided for in Section 11
      hereof; or

	 	
      (iv)
	
      Upon
      a Change of Control of Company (as such term is hereinafter
      defined).

10.2   
Permanent
Disability. If
Consultant becomes totally and permanently disabled (as defined in the Company’s
disability benefit plan applicable to senior executive officers as in effect on
the date thereof) (“Permanent Disability”), Company or Consultant may terminate
this Agreement on written notice thereof, and Consultant shall receive or
commence receiving, as soon as practicable:

 

5

 

	 	
      (i)
	
      amounts
      payable pursuant to the terms of the disability insurance policy or
      similar arrangement which Company maintains for the Consultant, if any,
      during the term hereof;

	 	
      (ii)
	
      the
      Compensation Payment which shall be paid to Consultant as a cash lump sum
      within 30 days of such termination; and

	 	
      (iii)
	
      immediate
      vesting of all unvested stock options.

10.3    
Death. In the
event of Consultant’s death during the term of his employment hereunder,
Consultant's estate or designated beneficiaries shall receive or commence
receiving, as soon as practicable in accordance with the terms of this
Agreement:

	 	
      (i)
	
      compensation
      equal to one year’s Base Compensation which shall be paid within 30 days
      of such termination;

	 	
      (ii)
	
      any
      death benefits provided under the Consultant benefit programs, plans and
      practices in which the Consultant has an interest, in accordance with
      their respective terms;

	 	
      (iii)
	
      the
      Compensation Payment which shall be paid to Consultant’s estate as a cash
      lump sum within 30 days of such termination;
and

	 	
      (iv)
	
      such
      other payments under applicable plans or programs to which Consultant's
      estate or designated beneficiaries are entitled pursuant to the terms of
      such plans or programs.

10.4   
Voluntary
Termination by Consultant: Discharge for Cause. The
Company shall have the right to terminate this Agreement for Cause (as
hereinafter defined). In the event that Consultant’s employment is terminated by
Company for Cause, as hereinafter defined, or by Consultant other than for Good
Reason or other than as a result of the Consultant’s Permanent Disability or
death, prior to the Termination Date, Consultant shall be entitled only to
receive, as a cash lump sum within 30 days of such termination the Compensation
Payment. As used herein, the term “Cause” shall be limited to (i) willful
malfeasance or willful misconduct by Consultant in connection with the services
to the Company in a matter of material importance to the conduct of the
Company's affairs which has a material adverse affect on the business of the
Company, (ii) willful continuing refusal by Consultant to perform his duties
hereunder as reasonably directed by the Board of Directors after notice of any
such refusal to perform such duties or such reasonable direction was given to
Consultant by the Board of Directors, or (iii) the conviction of Consultant for
commission of a felony. For purposes of this subsection, no act or failure to
act on the Consultant’s part shall be considered “willful” unless done, or
omitted to be done, by the Consultant not in good faith and without reasonable
belief that his action or omission was in the best interest of the Company.
Termination of this Agreement pursuant to this Section 10.4 shall be made by
delivery to Consultant of a

 

6

 

copy of a
resolution duly adopted by the affirmative vote of all of the members of the
Board of Directors called and held for such purpose (after 30 days prior written
notice to Consultant and reasonable opportunity for Consultant to be heard
before the Board of Directors prior to such vote), finding that in the good
faith business judgment of such Board of Directors, Consultant was guilty of
conduct set forth in any of clauses (i) through (iii) above and specifying the
particulars thereof.

11.       Assignment:

This
Agreement shall be binding upon and inure to the benefit of the heirs and
representatives of Consultant and the assigns and successors of Company, but
neither this Agreement nor any rights or obligations hereunder shall be
assignable or otherwise subject to hypothecation by Consultant (except by will
or by operation of the laws of intestate succession or by Consultant notifying
the Company that cash payment be made to an affiliated investment partnership in
which Consultant is a control person) or by Company, except that Company may
assign this Agreement to any successor (whether by merger, purchase or
otherwise) to all or substantially all of the stock, assets or businesses of
Company, if such successor expressly agrees to assume the obligations of Company
hereunder.

12.      
Change
In Control:

12.1   
Definition. For
purposes of this Agreement, a “Change in Control” shall be deemed to have
occurred if (i) there shall be consummated (A) any consolidation or merger of
the Company in which the Company is not the continuing or surviving corporation
or pursuant to which shares of the Company’s Common Stock would be converted
into cash, securities or other property, other than a merger of the Company in
which the holders of the Company’s Common Stock immediately prior to the merger
have substantially the same proportionate ownership of common stock of the
surviving corporation immediately after the merger, or (B) any sale, lease,
exchange or other transfer (in one transaction or a series of related
transactions) of all or substantially all the assets of the Company, or (ii) the
stockholders of the Company shall approve any plan or proposal for the
liquidation or dissolution of the Company, or (iii) any person (as such term is
used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the
“Exchange Act”)), other than the Company or any executive benefit plan sponsored
by the Company, or such person on the Effective Date hereof is a 20% or more
beneficial owner, shall become the beneficial owner (within the meaning of Rule
13d-3 under the Exchange Act) of securities of the Company representing 20% or
more of the combined voting power of the Company’s then outstanding securities
ordinarily (and apart from rights accruing in special circumstances) having the
right to vote in the election of directors, as a result of a tender or exchange
offer, open market purchases, privately negotiated purchases or otherwise, or
(iv) at any time during a period of two consecutive years, individuals who at
the beginning of such period, constituted the Board of Directors of the Company
shall cease for any reason to constitute at least a majority thereof, unless the
election or the nomination for election by the Company’s stockholders of each
new director during such two-year period was approved by a vote of at least
two-thirds of the directors then still in office, who were directors at the
beginning of such two-year period.

 

7

 

12.2   
Rights
and Obligations. If a
Change in Control of the Company shall have occurred while the Consultant is
director of the Company, the Consultant shall be entitled to the compensation
provided in Section 10.1 of this Agreement upon the subsequent termination of
this Agreement by either the Company, or the Consultant within two years of the
date upon which the Change in Control shall have occurred, unless such
termination is a result of (i) the Consultant’s death; (ii) the Consultant’s
Disability; (iii) the Consultant’s Retirement; or (iv) the Consultant’s
termination for Cause. 

13.      
Indemnification:

 

Consultant,
as such and as a Director of the Company, shall be indemnified by the Company
against all liability incurred by the Consultant in connection with any
proceeding, including, but not necessarily limited to, the amount of any
judgment obtained against Consultant, the amount of any settlement entered into
by the Consultant and any claimant with the approval of the Company, attorneys’
fees, actually and necessarily incurred by him in connection with the defense of
any action, suit, investigation or proceeding or similar legal activity,
regardless of whether criminal, civil, administrative or investigative in nature
(“Claim”), to which he is made a party or is otherwise subject to, by reason of
his being or having been a director, officer, agent or employee of the Company,
to the full extent permitted by applicable law and the Certificate of
Incorporation of the Company.. Such right of indemnification will not be deemed
exclusive of any other rights to which Consultant may be entitled under
Company’s Certificate of Incorporation or By-laws, as in effect from time to
time, any agreement or otherwise.

14.      
Miscellaneous:

a.     
This
Agreement between the Company and Consultant constitutes the entire agreement
and understanding of the parties hereto, and supersedes any and all previous
agreements and understandings, whether oral or written, between the parties with
respect to the matters set forth herein.

b.     
Any
notice or communication permitted or required hereunder shall be in writing and
shall be deemed sufficiently given if hand-delivered or sent (i) postage prepaid
by registered mail, return receipt requested, or (ii) by facsimile, to the
respective parties as set forth below, or to such other address as either party
may notify the other in writing.

 

 

	 	If to the Company, to:	 	Venus Beauty Supply, Inc.
	 	 	 	
      31-51
      Steinway Street

	 	 	 	Long Island City, NY 11103
	 	 	 	Attention: Sarah Booth, President
	 	 	 	 
	 	If to Consultant, to:	 	Gabriele M. Cerrone
	 	 	 	c/o Panetta Partners Ltd.
	 	 	 	1275 First Avenue, Suite 296
	 	 	 	
      New
      York, New York 10021

	 	 	 	
      Attention:
      Gabriele M. Cerrone, Managing Partner

 

8

 

	 		 	With a required copy to:
	 	 	 	
       

	 	 	 	Sommer & Schneider LLP
	 	 	 	595 Stewart Avenue, Suite 710
	 	 	 	Garden City, NY 11530
	 		 	Attention: Herb Sommer, Partner

 

c.     
This
Agreement may be executed in any number of counterparts, each of whom together
shall constitute one and the same original document.

d.     
This
Agreement may not be changed orally, but only by an agreement in writing signed
by the party against whom any waiver, change, amendment, modification or
discharge is sought.

e.     
The
invalidity of all or any part of any provision of this Agreement shall not
render invalid the remainder of this Agreement or the remainder of such
provision. If any provision of this Agreement is so broad as to be
unenforceable, such provision shall be interpreted to be only so broad as is
enforceable.

f.     
This
Agreement shall be governed by and construed in accordance with the law of the
State of New York without giving effect to the principles of conflicts of law
thereof. The parties hereto each hereby submits herself or itself for the sole
purpose of this Agreement and any controversy arising hereunder to the exclusive
jurisdiction of the state courts in the State of New York.

 

g.     
Any
amounts due hereunder to Consultant which remain unpaid after their due date,
shall bear interest from the due date until paid at a rate of the prime rate (in
effect on the date thereof for Citibank).

 

h.     
The
Company’s obligations to make payments under Section 10 and 12 shall survive
termination or expiration of this Agreement.

 

i.     
Consultant
shall not be required to mitigate damages or the amount of any payment provided
for under this Agreement by seeking other employment or otherwise after the
termination of this Agreement.

 

[SIGNATURE
PAGE FOLLOWS]

 

9

 

IN
WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed, as of the date
first above written.

 

	 	        	 
	 	CONSULTANT
	 
 	 
 	 
 
		   	/s/
      Gabriele M. Cerrone
	 	
      

    
	 	Gabriele M.
Cerrone

 

	 	 	 
	 	VENUS BEAUTY SUPPLY,
    INC.
	 
 	 
 	 
 
		By: 
      	/s/
      Sarah Boothe
	 	
      

    
	 	Name: Sarah Boothe
      Title:   
      President

 

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]